Expert Interviews

An expert discusses treatments for narcolepsy, comparing options for managing excessive daytime sleepiness (EDS) and cataplexy, and examines the advantages, limitations, and clinical scenarios for medications targeting EDS versus compared with those for both EDS and cataplexy.

A panelist discusses how neurokinin-targeted therapies can be strategically combined with existing treatments to address multiple vasomotor symptoms (VMS) while highlighting their positive impact on patient quality of life, noting ongoing needs for long-term safety data and improved accessibility.

A panelist discusses how payer contract requirements and reimbursement policies significantly influence their institution’s biosimilar adoption strategy, requiring careful analysis of net cost benefits when weighing potential savings against the operational complexities of managing multiple products.

An expert discusses how nintedanib and pirfenidone differ in their mechanisms of action and efficacy in treating idiopathic pulmonary fibrosis (IPF).

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in recent years, and identifies specific patient populations for whom steroids may remain a viable treatment option.

Menopausal patients are most interested in learning more about non-hormonal treatments to address their symptoms, according to the results of an international survey led by the Menopause Priority Setting Partnership (MAPS). Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health, discussed the survey details with Managed Healthcare Executive.

An expert discusses how key symptoms of narcolepsy, such as excessive daytime sleepiness and cataplexy, impact daily functioning and quality of life, along with the primary differences between type 1 and type 2 narcolepsy in terms of pathophysiology, clinical presentation, and diagnostic criteria.

A panelist discusses how their institution prioritizes cost savings and reliable supply chain considerations when selecting biosimilars for formulary inclusion, while also weighing switching study evidence, addressing stakeholder concerns through education, and implementing protocols to overcome barriers such as electronic health record integration and prior authorization challenges.

Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, talks with Managed Healthcare Executive about Robert F. Kennedy Jr., President Donald Trump’s HHS secretary nominee.

Potential threats to HIV care and fallout over the next four years, according to Jose Abrigo, Esq., HIV project director at Lambda Legal Defense and Education Fund and Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.

A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while prioritizing operational efficiency, patient access, and seamless transitions between reference products and biosimilars.

Panelists discuss the potential role of emerging treatments in the progressive pulmonary fibrosis (PPF) landscape if approved, exploring how they could address key unmet needs, improve patient outcomes, and optimize healthcare resource utilization.

Panelists provide an overview of emerging therapies for progressive pulmonary fibrosis (PPF), highlighting the latest developments and potential treatment options.

Panelists discuss the key gaps and unmet needs in current management strategies for progressive pulmonary fibrosis (PPF) and how ongoing research and collaborative efforts may help address these challenges.

Anna Podolanczuk, M.D., M.S., discusses the key unmet needs in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), and how artificial intelligence (AI) could play a transformative role in enabling earlier detection of these diseases in the future.

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses the current treatment landscape for progressive pulmonary fibrosis, highlighting nonpharmacological and pharmacological options to manage the disease.

Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these diseases from other respiratory conditions, as well as the role of biopsy and the histopathological features commonly seen in these diseases.

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses how progressive pulmonary fibrosis is diagnosed in clinical practice, the barriers hindering early diagnosis, strategies to overcome these challenges and the critical role of early detection and intervention in improving patient outcomes and reducing long-term healthcare costs.

Anna Podolanczuk, M.D., M.S., discusses how the differential diagnosis for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is approached, the importance of early diagnosis and why these diseases are often misdiagnosed.

Anna Podolanczuk, M.D., M.S., discusses how key epidemiological trends in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including changes in incidence and prevalence, contribute to the growing economic burden that patients with these conditions face.

Anna Podolanczuk, M.D., M.S., discusses how the mortality rates for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are impacted by comorbidities, including the role of autoimmune diseases in the pathophysiology of these conditions.

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses the most common symptoms of progressive pulmonary fibrosis (PPF), how they typically evolve and the impact of PPF on patients’ daily activities and quality of life as the disease progresses.

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses progressive pulmonary fibrosis, its primary causes and the key risk factors contributing to its development and progression.

Seemal Desai, M.D., FAAD, discusses how effective patient education and engagement strategies, combined with emerging telemedicine and digital health technologies, enhance vitiligo care delivery, disease monitoring and patient self-management capabilities.

Anna Podolanczuk, M.D., M.S., discusses how different types of interstitial lung diseases and their main risk factors contribute to the development of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), as well as how these diseases present with common symptoms and progress over time.

The panelist discusses how vitiligo’s psychological and social impacts significantly affect patients’ quality of life and treatment adherence, necessitating a holistic approach that addresses both physical symptoms and psychosocial support needs.

Our network connects providers, health plans, and life science companies to deliver seamless care that benefits everyone

Seemal Desai, M.D., FAAD, discusses how managed care organizations can improve access to advanced vitiligo treatments through updated formulary decisions and treatment algorithms while addressing insurance coverage barriers and balancing treatment aggressiveness with value-based care considerations.